Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer’s disease (2023)
- Authors:
- Ribeiro, Deidiane Elisa
- Petiz, Lyvia Lintzmaier - Universidade Federal do Paraná (UFPR)
- Glaser, Talita
- Giacomelli, Ágatha Oliveira
- Andrejew, Roberta
- Saab, Fernando de Azevedo Ribeiro
- Milanis, Milena da Silva
- Campos, Henrique Correia
- Sampaio, Vanessa Fernandes Arnaud
- La Banca, Sophia
- Longo, Beatriz Monteiro
- Lameu, Claudiana
- Tang, Yong
- Resende, Rodrigo Ribeiro
- Ferreira, Sergio T - Universidade Federal do Rio de Janeiro (UFRJ)
- Ulrich, Henning
- Ribeiro, Deidiane Elisa
- USP affiliated authors: ULRICH, ALEXANDER HENNING - IQ ; GLASER, TALITA - IQ ; GIACOMELLI, ÁGATHA OLIVEIRA - IQ ; SAAB, FERNANDO DE AZEVEDO RIBEIRO - IQ ; MILANIS, MILENA DA SILVA - IQ
- Unidade: IQ
- DOI: 10.1016/j.neuropharm.2022.109371
- Subjects: NEUROPSIQUIATRIA; DOENÇA DE ALZHEIMER; DEPRESSÃO; TRANSTORNOS DO SONO
- Agências de fomento:
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- Financiamento CNPq
- Financiamento PIPAE/PRP/USP
- Financiamento FAPEMIG
- Financiamento Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
- Financiamento Sichuan Province Science and Technology Program
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Neuropharmacology
- ISSN: 0028-3908
- Volume/Número/Paginação/Ano: v. 226, p. 1-16 art. 109371, 2023
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
RIBEIRO, Deidiane Elisa et al. Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer’s disease. Neuropharmacology, v. 226, p. 1-16 art. 109371, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2022.109371. Acesso em: 23 maio 2024. -
APA
Ribeiro, D. E., Petiz, L. L., Glaser, T., Giacomelli, Á. O., Andrejew, R., Saab, F. de A. R., et al. (2023). Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer’s disease. Neuropharmacology, 226, 1-16 art. 109371. doi:10.1016/j.neuropharm.2022.109371 -
NLM
Ribeiro DE, Petiz LL, Glaser T, Giacomelli ÁO, Andrejew R, Saab F de AR, Milanis M da S, Campos HC, Sampaio VFA, La Banca S, Longo BM, Lameu C, Tang Y, Resende RR, Ferreira ST, Ulrich H. Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer’s disease [Internet]. Neuropharmacology. 2023 ; 226 1-16 art. 109371.[citado 2024 maio 23 ] Available from: https://doi.org/10.1016/j.neuropharm.2022.109371 -
Vancouver
Ribeiro DE, Petiz LL, Glaser T, Giacomelli ÁO, Andrejew R, Saab F de AR, Milanis M da S, Campos HC, Sampaio VFA, La Banca S, Longo BM, Lameu C, Tang Y, Resende RR, Ferreira ST, Ulrich H. Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer’s disease [Internet]. Neuropharmacology. 2023 ; 226 1-16 art. 109371.[citado 2024 maio 23 ] Available from: https://doi.org/10.1016/j.neuropharm.2022.109371 - Stem cells: principles and applications
- ATP and spontaneous calcium oscillations control neural stem cell fate determination in Huntington’s disease: a novel approach for cell clock research
- Neuroprotective effects of resistance physical exercise on the APP/PS1 mouse model of Alzheimer’s disease
- The P2X7 receptor: central hub of brain diseases
- Purinergic receptors in basal ganglia diseases: shared molecular Mechanisms between huntington’s and parkinson’s disease
- Selection and application of aptamer affinity for protein purification
- Purinergic Signaling in Neurodevelopment, Neuroinflammation and Neurodegeneration
- Purinergic receptors in neurogenic processes
- Purinergic signaling: an overview
- The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis
Informações sobre o DOI: 10.1016/j.neuropharm.2022.109371 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 3119892.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
